1 BTC
=
- USD
Harmony Biosciences Holdings, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Harmony Biosciences Holdings, Inc. Common Stock
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Market Statistics
Trading Metrics
How to Buy HRMY
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy HRMY
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesBridge City Capital fully exited its position in Harmony Biosciences Holdings, selling all 237,103 shares worth approximately $7.77 million during Q1 2026. The stake, which represented 2.6% of the fund's AUM in the prior quarter, was completely liquidated. Harmony Biosciences, a rare neurological disorder treatment developer, has underperformed the S&P 500 by 42.07 percentage points over the past year.
The Russell 2000 small-cap index has outperformed major indices, rising 8.40% in the past month. With Q1 2026 earnings season underway, analysts expect small-cap earnings growth of 18.4% compared to 9.8% for S&P 500 companies. The article highlights three undervalued small-cap stocks with significant upside potential: Goosehead Insurance (technology-driven insurance broker), EverCommerce (SaaS platform for service businesses), and Harmony Biosciences (rare disease biopharmaceutical company).
Harmony Biosciences' CFO Sandip Kapadia sold all 20,961 of her directly held shares for approximately $752,800 on January 15, 2026, fully exiting her equity position. The sale was part of a pre-planned Rule 10b5-1 trading plan. Despite the insider exit, the company reported strong Q3 2025 earnings and expects to generate over $1 billion in revenue from its flagship product WAKIX by end of 2026.
Harmony Biosciences has achieved remarkable financial success with its narcolepsy drug Wakix, growing sales at 40% CAGR to nearly $870 million and achieving profitability with $186 million in net income. However, the stock has remained flat since its IPO due to concerns including a 2023 short-seller report alleging fraud, pending patent expiration in 2030, and intense competition from Jazz Pharmaceuticals' blockbuster treatments Xywav and Xyrem.
The Developmental and Epileptic Encephalopathies (DEE) market is expected to grow significantly due to approved medications like EPIDIOLEX, rising demand for novel treatments, and the introduction of potential emerging therapies. However, the discontinuation of emerging therapies may impede this growth.
